Newsroom | 9628 results

BOSTON--(BUSINESS WIRE)--Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, today announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification. Enrollment is underway at three of more than 20 planned sites across the U.S., Europe, and Asia: Emory University, the Medical University of South Carolina, and Centro Cardiologico Monzino, Milan, led...

NEW YORK & SEOUL--(BUSINESS WIRE)--AccurKardia, Inc., an ECG-led diagnostics software company, and Wellysis, a digital healthcare company and developer of the S-Patch wearable ECG monitor, today announced a multi-year agreement under which AccurKardia’s AccurECG 2.0 will power the analytics behind Wellysis’ turnkey cardiac monitoring offering in the U.S. The agreement, which was signed last week in Seoul, is the latest between the two companies.Under the agreement, Wellysis’ S-Patch wearable dev...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner AstraZeneca today announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not meet the primary efficacy endpoint of the composite outcome of cardiovascular (CV) mortality and recurrent CV clinical events up to Week 140 compared with placebo. In this contemporary patient population treated with standard of care, includin...

RICHMOND HILL, N.Y.--(BUSINESS WIRE)--iHealthScreen, Inc., a healthcare AI company developing Software as a Medical Device (SaMD) for retinal and cardiovascular disease screening and preventive healthcare, today announced FDA 510(k) clearance (K253704) for iPredict-DR™, its AI-powered software that automatically detects more than mild diabetic retinopathy (mtmDR) in adults with diabetes not previously diagnosed with the condition. Diabetic retinopathy is a leading cause of preventable blindness...

MIAMI & BOSTON--(BUSINESS WIRE)--OpenEvidence and the Anticoagulation Forum (AC Forum) today announced a strategic partnership to provide antithrombotic guidance and tools that support decision-making in clinical practice. By combining the AC Forum’s leadership in education and multidisciplinary clinical guidance with OpenEvidence’s advanced artificial intelligence platform, clinicians will gain access to timely and practical evidence in antithrombotic therapy. “Clinicians are increasingly turn...

KIRKLAND, Wash.--(BUSINESS WIRE)--Cardiac Dimensions, a leader in transcatheter therapies for heart failure, today announced the publication of three major manuscripts that together form the most comprehensive evidence base ever assembled for transcatheter indirect mitral annuloplasty. These publications span a five-year multi-center commercial registry, the largest single-center experience across both preserved and reduced ejection fraction, and long-term survival results through ten years. Th...

WOODBURY, Minn.--(BUSINESS WIRE)--Veterinary Dentistry Specialists® (VDS) is pleased to announce the addition of veterinary cardiology services at its Twin Cities practice, partnering with board-certified veterinary cardiologist Michelle Rose, DVM, DACVIM (Cardiology), of Twin Cities Veterinary Cardiology.Operating Tuesdays through Thursdays from 8:00 AM to 4:00 PM starting July 14, 2026, this new service supports the VDS mission to provide the safest, most advanced dentistry and oral surgery fo...

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform...

AURORA, Colo. & WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global life sciences company, has announced a new strategic alliance focused on clinical trials collaboration with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, establishing Bayer’s first alliance of its kind with an academic medical center. The initiative reflects a shared commitment to accelerating clinical research through stronger collaboration between industry and academic medicine. The alliance is...

DENVER--(BUSINESS WIRE)--Cleerly, a leader in advanced cardiovascular imaging analysis, will be attending the 21st Annual Scientific Meeting of the Society of Cardiovascular Computed Tomography (SCCT2026). The conference will take place July 9–12, 2026, at the Gaylord Pacific Resort in Chula Vista, California. SCCT2026 brings together clinicians and researchers from around the world to advance the science and practice of cardiovascular computed tomography. Cleerly will debut new customization c...